Bioatla, INC 10-Q quarterly reports

BioAtla reports Q1 2026 financial results, highlighting a strategic shift, workforce reduction, and a $6.5 million amendment to its Context Therapeutics license agreement.

BioAtla, a clinical-stage biopharmaceutical company, reported a net loss of $15.8 million for Q3 2025 and $49.8 million for the nine months ended September 30, 2025, with management expressing substantial doubt about its ability to continue as a going concern.

BioAtla, a clinical-stage biopharmaceutical company, reported significant losses and a critical cash position, raising substantial doubt about its ability to continue as a going concern, while also facing Nasdaq delisting.

BioAtla, Inc. announces its Q1 2025 financial results, highlighting a net loss of $15.3 million and a corporate restructuring including a 30% workforce reduction.

BioAtla, Inc. reported a net loss of $10.6 million for the third quarter of 2024, with revenue of $11 million driven by a licensing agreement.

BioAtla, a clinical-stage biopharmaceutical company, reported a decrease in operating expenses and a net loss for the second quarter of 2024, while maintaining a sufficient cash position to fund operations for at least the next twelve months.

BioAtla's first quarter 2024 results show a net loss of $23.2 million, with a focus on advancing clinical trials and managing cash reserves.